Search

Your search keyword '"Marchand, Marie"' showing total 340 results
Start Over Author "Marchand, Marie"
340 results on '"Marchand, Marie"'

4. Couverture

Author

Marchand, Marie-Eve

Published
2019

11. Annexe

Author

Marchand, Marie-Eve

Published
2019

24. Préface

Author

Marchand, Marie-Eve

Published
2019

27. Introduction

Author

Marchand, Marie-Eve

Published
2019

29. The Role of Intuition in Evaluative Judgment and Decision

Author

Hurteau, Marthe, Rahmanian, Jeiran, Houle, Sylvain, and Marchand, Marie-Pier

Abstract

Expert intuition is increasingly considered to be a valid form of knowledge, and research has proven its effectiveness in judgment and decision making in various fields. Theorists seem to recognize the contributions of intuition within evaluative practice, but it has never been well-documented. This article presents a study on expert intuition, addressing the manner in which intuition is developed, as well as how it contributes to producing judgments in the specific context of program evaluation. In-depth, in-person interviews were conducted with eight novice evaluators and eight experienced evaluators in order to assess the contributions of experience and expertise. Two key observations emerged from interview analyses. The first was that intuition is developed through a long, complex, and demanding process in which reflective analysis of experiments, successes, and failures play an essential role; the second was that the development of intuition is fostered by expertise and experience.

Published
2020
Full Text
View/download PDF

39. Entre jeux de pouvoir et intérêts: retour à la raison d'être de l'évaluation.

Author

Marchand, Marie-Pier and Hurteau, Marthe

Subjects
EVALUATORS, DISCOURSE
Abstract

Copyright of Mesure et Évaluation en Éducation is the property of ADMEE-Canada and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

47. Supplementary Figure Legends 1-6 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells

Author

François, Violaine, primary, Ottaviani, Sabrina, primary, Renkvist, Nicolina, primary, Stockis, Julie, primary, Schuler, Gerold, primary, Thielemans, Kris, primary, Colau, Didier, primary, Marchand, Marie, primary, Boon, Thierry, primary, Lucas, Sophie, primary, and van der Bruggen, Pierre, primary

Published
2023
Full Text
View/download PDF

48. L’accès aux soins palliatifs, équitable pour tous? Le cas des personnes en fin de vie vivant l’itinérance

Author

Marchand, Marie-Hélène

Subjects
end of life, social precarity, equity, palliative care, itinérance, soins palliatifs, accessibility to care, équité, fin de vie, homelessness, précarité sociale, accessibilité aux soins
Abstract

Every human being will at some point be exposed to some degree of suffering. One segment of the population, people experiencing homelessness, will be much more likely to experience death, illness and bereavement. In Quebec, they are four times more likely to develop cancer and their life expectancy is between 42 and 52 years. The high mortality and morbidity of the homeless population raises the following question: do these individuals have equitable access to palliative care resources? The arrival of Bill 2 in 2015, allowed for the regulation of end-of-life care in Quebec. At the heart of this law is the right of patients at the end of life to have access to palliative care to prevent and ease their suffering. Several issues influence the accessibility of palliative care for the homeless population. Individual factors such as mental illness and substance abuse complicate access to care. The distrust of individuals with multiple traumatic experiences adds another barrier. In addition, these individuals are too busy surviving to navigate the health care system. Structural factors, such as the lack of affordable housing or the impact of a siloed system less suited to complex social situations, contribute to a lack of accessibility. Prejudice is widespread, contributing to the symbolic and institutional exclusion of this population. The objective of this article is therefore to deepen our understanding of the issues of access to palliative care for the homeless population in Quebec., Tout être humain sera exposé un jour à un certain degré de souffrance. Une tranche de la population, les personnes vivant l’itinérance, sera cependant beaucoup plus susceptible de côtoyer la mort, la maladie et les deuils. En effet, au Québec, elles sont quatre fois plus à risque de développer un cancer et leur espérance de vie se situe entre 42 et 52 ans. Devant la mortalité et la morbidité élevées rencontrées dans la population itinérante est soulevée cette question: est-ce que ces individus ont un accès équitable aux ressources en soins palliatifs? L’arrivée de la Loi 2 en 2015 a permis d’encadrer les soins de fin de vie au Québec. Au cœur de cette loi se trouve le droit des malades en fin de vie d’avoir accès à des soins palliatifs pour prévenir et apaiser leurs souffrances. Or, plusieurs enjeux viennent influencer l’accessibilité aux soins palliatifs pour la population itinérante, notamment des facteurs individuels tels que la maladie mentale et la dépendance aux substances, compliquant la recherche de soins. La méfiance des individus ayant vécu de multiples expériences traumatiques ajoute une barrière supplémentaire. De plus, trop occupées à survivre, ces personnes naviguent difficilement dans le système de santé. Des facteurs structuraux, tels l’absence de logements abordables ou les répercussions d’un système en silos moins adapté aux situations sociales complexes contribuent au manque d’accessibilité. Les préjugés sont très répandus, participant à l’exclusion symbolique et institutionnelle de cette population. L’objectif de cet article sera donc d’approfondir notre compréhension des enjeux d’accès aux soins palliatifs pour la population en situation d’itinérance au Québec.

Published
2022

49. Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous women identified by uterine artery Doppler as at high risk of preeclampsia: A double blinded randomized placebo-controlled trial

Author

Diguisto, Caroline, Le Gouge, Amelie, Marchand, Marie-Sara, Megier, Pascal, Ville, Yves, Haddad, Georges, Winer, Norbert, Arthuis, Chloé, Doret, Muriel, Debarge, Veronique Houfflin, Flandrin, Anaig, Delmas, Hélène Laurichesse, Gallot, Denis, Mares, Pierre, Vayssiere, Christophe, Sentilhes, Loïc, Cheve, Marie-Therese, Paumier, Anne, Durin, Luc, Schaub, Bruno, Equy, Veronique, Giraudeau, Bruno, Perrotin, Franck, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Maternité Olympe de Gouges [CHRU Tours], Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional d'Orléans (CHRO), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), CHU Lille, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Clermont-Ferrand, Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Aix-Marseille Université - École de maïeutique (AMU SMPM EM), Aix-Marseille Université - Faculté des sciences médicales et paramédicales (AMU SMPM), Aix Marseille Université (AMU)-Aix Marseille Université (AMU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Centre Hospitalier Le Mans (CH Le Mans), Polyclinique de l’Atlantique, Partenaires INRAE, Elsan Polyclinique du Parc - Caen, CHU de la Martinique [Fort de France], CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, and Université de Tours (UT)

Subjects
Male, Uterine Artery, Pregnancy Trimester, First, Multidisciplinary, Pre-Eclampsia, Aspirin, Pregnancy, [SDV]Life Sciences [q-bio], Infant, Newborn, Humans, Birth Weight, Female
Abstract

Introduction This trial evaluates whether daily low-dose aspirin initiated before 16 weeks of gestation can reduce preeclampsia and fetal growth restriction in nulliparous women identified by first-trimester uterine artery Dopplers as at high risk of preeclampsia. Methods This randomized, blinded, placebo-controlled, parallel-group trial took place in 17 French obstetric departments providing antenatal care. Pregnant nulliparous women aged ≥ 18 years with a singleton pregnancy at a gestational age < 16 weeks of gestation with a lowest pulsatility index ≥ 1.7 or a bilateral protodiastolic notching for both uterine arteries on an ultrasound performed between 11+0 and 13+6 weeks by a certified sonographer were randomized at a 1:1 ratio to 160 mg of low-dose aspirin or to placebo to be taken daily from inclusion to their 34th week of gestation. The main outcome was preeclampsia or a birthweight ≤ 5th percentile. Other outcomes included preeclampsia, severe preeclampsia, preterm preeclampsia, preterm delivery before 34 weeks, mode of delivery, type of anesthesia, birthweight ≤ 5th percentile and perinatal death. Results The trial was interrupted due to recruiting difficulties. Between June 2012 and June 2016, 1104 women were randomized, two withdrew consent, and two had terminations of pregnancies. Preeclampsia or a birthweight ≤ 5th percentile occurred in 88 (16.0%) women in the low-dose aspirin group and in 79 (14.4%) in the placebo group (proportion difference 1.6 [-2.6; 5.9] p = 0.45). The two groups did not differ significantly for the secondary outcomes. Conclusion Low-dose aspirin was not associated with a lower rate of either preeclampsia or birthweight ≤ 5th percentile in women identified by their first-trimester uterine artery Doppler as at high risk of preeclampsia. Trial registration (NCT0172946).

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results